Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody
consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β)
trap in subjects with locally advanced or metastatic cancers